Lyrica is the brand name for pregabalin, a prescription medication used for nerve pain, fibromyalgia, and certain seizure disorders. Employees who take it, and the employers who test them, often want to know whether a routine workplace drug screen will flag it. The short answer is that a standard drug test panel almost never looks for pregabalin at all. It is not one of the substances that the common five panel, ten panel, or federally regulated transportation panels are built to detect. It only shows up when someone specifically orders a gabapentinoid test.
This matters because pregabalin is a controlled substance, and because a small but growing number of workplace and clinical drug testing programs are starting to add gabapentinoid screening for reasons unrelated to typical drug misuse concerns. Understanding what is actually being tested for, and why, helps employers set expectations correctly and helps employees know what a positive or a missing result actually means.
What Lyrica Is and Why It Is Scheduled
Pregabalin works on the central nervous system and is approved for conditions such as diabetic nerve pain, pain following shingles (postherpetic neuralgia), spinal cord injury pain, fibromyalgia, and as an add on therapy for partial onset seizures, according to the FDA approved prescribing information on file with the National Library of Medicine. It carries a boxed warning and other precautions, and it is dispensed only by prescription.
Federally, pregabalin is classified as a Schedule V controlled substance under the Controlled Substances Act. The Drug Enforcement Administration placed it there because of documented abuse potential, though Schedule V represents the lowest abuse potential category among scheduled drugs, a tier that also includes some cough preparations with limited codeine content. That scheduling is confirmed both in the drug label itself and in the federal regulation that lists controlled substances by schedule. Because it is a controlled substance, a valid prescription and normal medical documentation are what an employer or a medical review officer would expect to see if the drug is ever detected.
Why Standard Panels Do Not Catch It
Workplace drug testing panels are built around a specific, defined list of analytes, not around every prescription drug that could theoretically affect someone at work. The federal mandatory guidelines that govern testing for federal employees and for safety sensitive transportation workers spell out exactly which drug classes get tested and at what cutoff concentrations. Pregabalin, and gabapentinoids generally, are not on that list.
| Panel type | Typical analytes | Tests for pregabalin or gabapentin |
|---|---|---|
| Federal 5 panel (SAMHSA and DOT regulated testing) | Marijuana metabolites, cocaine metabolite, opiates, phencyclidine, amphetamines and methamphetamine | No |
| Common private employer 9 to 12 panel | The federal 5 plus some combination of benzodiazepines, barbiturates, methadone, propoxyphene, and MDMA | No |
| Expanded opioid panels | Prescription opioids beyond the basic opiate class, such as oxycodone or fentanyl analogs | No |
| Gabapentinoid specific add on test | Pregabalin and gabapentin only, ordered separately from a standard immunoassay | Yes, when specifically requested |
Testing that falls under Department of Transportation rules follows a fixed federal panel, and the drugs in that panel are set by regulation rather than by an individual employer's preference. That panel does not include gabapentinoids, and it generally cannot be modified on a per employer basis without going through the federal mandatory guidelines process. Non regulated employers have more flexibility and can ask a laboratory to add specific analytes, including a gabapentinoid panel, but most standard order forms do not include it by default.
When a Gabapentinoid Test Gets Added
Some pain management clinics, addiction treatment programs, and a smaller number of workplace programs now order pregabalin or gabapentin testing specifically. This usually happens for one of a few reasons: to confirm that a patient prescribed pregabalin is actually taking it as directed, to check for gabapentinoid misuse in a population where that has become a documented concern such as opioid treatment settings, or as part of a broader medication monitoring panel in a clinical rather than pre employment context. When this happens, the lab typically runs a dedicated immunoassay or a confirmatory method such as liquid chromatography tandem mass spectrometry, since pregabalin is not reliably picked up by the antibody based immunoassays used for the standard drug classes.
How Long Pregabalin Stays in the Body
Pregabalin is eliminated primarily through the kidneys largely unchanged, and it has a comparatively short elimination half life. In people with normal kidney function, the average elimination half life is about 6.3 hours, according to a pharmacology review published on the National Library of Medicine's Bookshelf platform. Using the general rule that a drug is largely cleared from the body after roughly four to five half lives, pregabalin itself tends to clear from the bloodstream within a day or so in someone with normal kidney function.
That estimate describes how quickly the drug leaves the body, not how long a specific laboratory test can detect it, since detection also depends on the assay's cutoff level, the specimen type, and the individual's kidney function. Reduced kidney function slows pregabalin clearance considerably, since its elimination is closely tied to creatinine clearance. Anyone asking about an exact detection window for a specific test should treat published averages as a general guide rather than a guarantee, since the laboratory performing the test sets the actual reporting cutoff.
What Happens If a Test Does Come Back Positive
When an employer orders a test that includes pregabalin and a result comes back positive, the standard process is the same one used for any other prescription medication that turns up on a screen. A certifying scientist confirms the result, and a medical review officer contacts the employee to ask about current prescriptions and supporting documentation before the result is reported to the employer. A valid, current prescription for Lyrica or generic pregabalin is normal supporting documentation for that conversation. Employers should not assume that a positive gabapentinoid result means misuse; it may simply reflect legitimate prescribed use, and the medical review officer process exists specifically to sort that out before any employment decision is made.
Employers building or updating a testing policy that includes gabapentinoids should also remember that rules on what can be tested, how results are handled, and what documentation an employee can provide vary by state and by whether the position is subject to federal transportation testing rules. A workplace policy should be reviewed by qualified counsel or a certified medical review officer before it is applied to employees.
Frequently asked questions
Does a standard 5 panel or 10 panel drug test detect Lyrica?
No. The federal 5 panel and the common private employer 9 to 12 panel tests screen for marijuana metabolites, cocaine, opiates, PCP, amphetamines, and sometimes benzodiazepines, barbiturates, or methadone. Pregabalin is not one of the analytes included in those standard panels.
Is Lyrica a controlled substance?
Yes. Pregabalin, the active ingredient in Lyrica, is a Schedule V controlled substance under the federal Controlled Substances Act, a status confirmed in the drug's FDA approved label and in the federal schedule of controlled substances.
Can an employer specifically test for pregabalin?
Yes, but it requires ordering a gabapentinoid specific test separately from a standard drug panel. Most routine workplace tests do not include this analyte unless a lab is specifically instructed to add it.
How long does Lyrica stay in your system?
Pregabalin has an average elimination half life of about 6.3 hours in people with normal kidney function, so it tends to clear from the bloodstream within roughly a day for most people. The exact window that any specific laboratory test can detect varies by the assay used and by individual kidney function, so treat this as a general range rather than a fixed number.
Will a prescription for Lyrica cause a problem if it does show up on a test?
A positive result for a prescribed medication is normally reviewed by a medical review officer, who contacts the employee to verify current prescription documentation before anything is reported to the employer. A valid, current prescription is standard documentation for that review.
Is gabapentin tested the same way as Lyrica?
Gabapentin and pregabalin are both gabapentinoids and are usually screened for together on the same specialty panel when a lab offers one, but neither is part of the standard workplace drug testing panels used for pre employment or DOT regulated testing.
Sources and Further Reading
For more background on standard drug testing programs and prescription drug review, see American Screening Corporation's guides to gabapentin and drug testing and the medical review officer process. Employers building or reviewing a testing program can find compliant drug test cups for standard panel testing.
Primary sources used in this article:
- 21 CFR 1308.15, Schedule V controlled substances (eCFR, U.S. Government Publishing Office)
- 49 CFR 40.85, cutoff concentrations for federally regulated urine drug tests (eCFR)
- Pregabalin, StatPearls (National Library of Medicine, NIH Bookshelf)
- LYRICA (pregabalin) prescribing information (DailyMed, National Library of Medicine)
- Pregabalin, MedlinePlus Drug Information (National Library of Medicine, NIH)
- Workplace drug testing programs (Substance Abuse and Mental Health Services Administration)
This article is general information for employers and employees, not legal or medical advice. Drug testing rules vary by state and by regulatory program, and any testing policy should be reviewed by qualified counsel or a certified medical review officer before it is applied.
